

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 October 2006 (05.10.2006)

PCT

(10) International Publication Number
WO 2006/104917 A2

(51) International Patent Classification:
A61K 31/519 (2006.01) **C07D 487/02** (2006.01)

(21) International Application Number:
PCT/US2006/010859

(22) International Filing Date: 24 March 2006 (24.03.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/665,154 25 March 2005 (25.03.2005) US

(71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CALLAHAN, James, Francis** [US/US]; 709 Swedeland Road, King Of Prussia, Pennsylvania 19406 (US). **BOEHM, Jeffrey** [US/US]; 709 Swedeland Road, King Of Prussia, Pennsylvania 19406 (US). **WAN, Zehong** [CN/US]; 709 Swedeland Road, King Of Prussia, Pennsylvania 19406 (US). **YAN, Hongxing** [CN/US]; 709 Swedeland Road, King Of Prussia, Pennsylvania 19406 (US).

(74) Agents: **DINNER, Dara, L.** et al.; GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, UW2220, 709 Swedeland Road, P.o. Box 1539, King Of Prussia, Pennsylvania 19406-0939 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR PREPARING PYRIDO[2,3-D]PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE DERIVATIVES

(57) Abstract: The present invention is directed to a novel method of preparing of 2,4,8- trisubstituted pyrido[2,3-d]pyrimidin-7-one pharmacophores of Formula (II) or (Ha) wherein GHs CH₂ Or NH: G2 is CH or nitrogen; Rx is chloro, bromo, iodo, or O-S(O)₂CF₃; Rg is a C₁₋₁₀ alkyl; m is 0, or an integer having a value of 1, or 2; R₃ is a C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl C₁₋₁₀ alkyl, aryl, arylC₁₋₁₀ alkyl, heteroaryl, heteroarylC₁₋₁₀ alkyl, heterocyclic or a heterocyclylC₁₋₁₀ alkyl moiety, and wherein each of these moieties may be optionally substituted. which comprises reacting a compound of the formula: wherein Ry is chloro, bromo, iodo, O-S(O)₂CF₃; and Rg is a C₁₋₁₀ alkyl; with a olefin forming reagent in a suitable base to yield a compound of Formula (II), or (Ha) wherein m=0 and oxidizing the sulphur as necessary or desired.

WO 2006/104917 A2